Project cooperationUpdated on 15 December 2025
Research tools and solutions for lipid nanoparticles (LNPs)
CEO at Anthelos KFT
Szeged, Hungary
About
Anthelos mission is to offer a portfolio of specialized research tools and solutions for LNP-related developments and therapies.
Anthelos provides research laboratories and biotech companies with analysis and molecular laboratory testing tools to deliver professional data on Lipid Nanoparticles (LNP) formulation, optimization, characterization, in vitro and in vivo functional tests.
Anthelos expertise in LNPs covers microfluidics design and production with its flexible nanoparticle generating system, LNP characterization, stability tests with its scanning nanoparticle tracking analysis system for tailored LNP formulations to optimize drug delivery for the clients’ specific therapeutic needs.
Efficiency and toxicity studies can be performed by Anthelos in primary immune cells (B-, T-cells), liver and DC cells with plate imaging and FACS analysis. Cell-type specific transfection efficiency analysis of different tissues can be done with confocal fluorescent microscopy. Anthelos applies in vivo imaging by using the company’s custom tailored in vivo imaging system with superior sensitivity for full body imaging, tissue distribution, organ- and cancer-specific targeting projects.
Anthelos is developing novel lipids and lipid additives to enhance LNP effectivity and specific targeting to pancrease, lungs and spleen.
Similar opportunities
Project cooperation
LNP delivery with barcoded mRNA
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
Filip Van Nieuwerburgh
Professor at Ghent University
Ghent, Belgium
Project cooperation
Medical education collaboration
- Consortium/Coordinator seeks Partners
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
Luca Takács
Founder and CEO at LNP Academy
Budapest, Hungary
Project cooperation
Inge Nelissen
R&D project manager at VITO nv
Mol, Belgium